Webcast - CHMP rekommenderar att Oncopeptides Pepaxti får ett fullt godkännande i EU

June 23, 2022, the European Medicines Agency´s (EMA) Committee for Medicinal Products for Human Use (CHMP), has unanimously adopted a positive opinion recommending a full marketing authorization approval (MAA) of Pepaxti® (melphalan flufenamide, also called melflufen) in EU. 

Conference call for investors, analysts, and media
Investors, financial analysts, and media are invited to participate in a webcast with a Q&A session on June 27, 2022, at 11:00 (CET). The event will be hosted by CEO Jakob Lindberg, CMO Klaas Bakker and CFO Annika Muskantor.

The webcast will be streamed via https://tv.streamfabriken.com/2022-pressconference.

Dial-in number
SE: +46856642695
UK: +443333009270
US: +16467224902

Link to the press release